AVENUE THERAPEUTICS, INC.
Close on Oct 16, 2026
- Market cap
- $1.42M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | – | $-1.92 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 9, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 18, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | During market hours | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 10, 2023 | During market hours | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 12, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 30, 2023 | During market hours | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 10, 2022 | During market hours | – | – | – |
| Q2 FY2020 Ended Jun 30, 2020 | Aug 14, 2020 | Before market open | – | – | – |
| Q1 FY2020 Ended Mar 31, 2020 | May 11, 2020 | Before market open | – | – | – |
| Q4 FY2019 Ended Dec 31, 2019 | Mar 30, 2020 | Before market open | – | – | – |
Press releases
Announcements Avenue Therapeutics filed with the SEC
Avenue Therapeutics Enters into Exclusive Worldwide
Material agreement · Other events · EX-99.1 to Form 8-K
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Avenue Therapeutics Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Avenue Therapeutics Reports Full Year 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Announces Pricing of $5.0 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Avenue Therapeutics Announces Closing of $5.0
Material agreement · Other events · EX-99.2 to Form 8-K
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Avenue Therapeutics Reports First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Avenue Therapeutics Announces Regulatory Update
Other events · EX-99.1 to Form 8-K
Avenue Therapeutics Reports Full Year 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates
Executive or director change · Other events · EX-99.1 to Form 8-K
Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Avenue Therapeutics Announces Closing of $3.25
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Avenue Therapeutics Reports Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Avenue Therapeutics Completes the Acquisition
Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Closing of $12 Million Underwritten Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Avenue Therapeutics Announces Reverse Stock
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Avenue Therapeutics Announces Outcome of FDA Advisory
Other events · EX-99.1 to Form 8-K